| Market Cap | 30.25M | P/E | - | EPS this Y | 52.60% | Ern Qtrly Grth | - |
| Income | -33.76M | Forward P/E | -0.13 | EPS next Y | 5.10% | 50D Avg Chg | -17.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 15.00% |
| Dividend | N/A | Price/Book | 1.76 | EPS next 5Y | - | 52W High Chg | -48.00% |
| Recommedations | 1.60 | Quick Ratio | 4.63 | Shares Outstanding | 10.69M | 52W Low Chg | 225.00% |
| Insider Own | 0.87% | ROA | -26.36% | Shares Float | 7.04M | Beta | 2.59 |
| Inst Own | 93.39% | ROE | -59.52% | Shares Shorted/Prior | 1.18M/623.88K | Price | 6.86 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 25,833 | Target Price | 80.60 |
| Oper. Margin | - | Earnings Date | Aug 6 | Volume | 7,185 | Change | -5.25% |
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
| Oppenheimer | Outperform | Jul 10, 24 |
| B. Riley Securities | Buy | Jun 26, 24 |
| RBC Capital | Outperform | Jun 11, 24 |
| Oppenheimer | Outperform | Jun 3, 24 |
| RBC Capital | Outperform | May 13, 24 |
| Oppenheimer | Outperform | May 8, 24 |
| Oppenheimer | Outperform | Mar 13, 24 |
| Jefferies | Buy | Mar 6, 24 |
| Oppenheimer | Outperform | Jan 29, 24 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| HOLMER ALAN F | Director Director | Jan 26 | Option | 4.97 | 629 | 3,126 | 1,379 | 01/30/24 |
| Cohen Yuval | Chief Executive Offi.. Chief Executive Officer | Jan 26 | Option | 4.97 | 7,179 | 35,680 | 7,179 | 01/30/24 |
| Millian Craig Stuart | Chief Operating Offi.. Chief Operating Officer | Aug 10 | Buy | 0.2545 | 5,000 | 1,272 | 27,000 | 08/12/22 |
| Cohen Yuval | Chief Executive Offi.. Chief Executive Officer | Aug 10 | Buy | 0.264 | 3,800 | 1,003 | 98,230 | 08/11/22 |
| Moran Sean F. | Chief Financial Offi.. Chief Financial Officer | Aug 10 | Buy | 0.2599 | 20,000 | 5,198 | 199,272 | 08/10/22 |
| Moran Sean F. | Chief Financial Offi.. Chief Financial Officer | May 16 | Buy | 0.30 | 12,000 | 3,600 | 179,272 | 05/16/22 |
| Cohen Yuval | Chief Executive Offi.. Chief Executive Officer | May 16 | Buy | 0.25 | 10,500 | 2,625 | 94,430 | 05/16/22 |
| Millian Craig Stuart | Chief Operating Offi.. Chief Operating Officer | Mar 10 | Buy | 0.37 | 10,000 | 3,700 | 22,000 | 03/11/22 |
| Moran Sean F. | Chief Financial Offi.. Chief Financial Officer | Mar 10 | Buy | 0.37 | 15,000 | 5,550 | 167,272 | 03/10/22 |
| Cohen Yuval | Chief Executive Offi.. Chief Executive Officer | Mar 09 | Buy | 0.37 | 8,600 | 3,182 | 83,930 | 03/09/22 |
| Moran Sean F. | Chief Financial Offi.. Chief Financial Officer | Dec 18 | Option | 0.17 | 36,923 | 6,277 | 386,533 | 12/18/20 |
| Moran Sean F. | Chief Financial Offi.. Chief Financial Officer | Dec 18 | Sell | 1.32 | 36,923 | 48,738 | 349,610 | 12/18/20 |